Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoFRA:0DX -3.38%19 6-1 Month Momentum % is -1.48% as of Aug. 25, 2026. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,380 Biotechnology companies, Nanjing Leads Biolabs Co ranks better than 65.22% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-25), Nanjing Leads Biolabs Co's 6-1 Month Momentum % is -1.48%.
The industry rank for Nanjing Leads Biolabs Co's 6-1 Month Momentum % or its related term are showing as below:
FRA:0DX's 6-1 Month Momentum % is ranked better than 65.22% of 1380
companies
in the Biotechnology industry
Industry Median: -17.2
vs FRA:0DX: -1.48
Nanjing Leads Biolabs Co (FRA:0DX) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Nanjing Leads Biolabs Co 6-1 Month Momentum % Related Terms
FRA:0DX vs VRTX, REGN, RVMD: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's 6-1 Month Momentum % falls into.
Nanjing Leads Biolabs Co (FRA:0DX) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (FRA:0DX) has a 6-1 Month Momentum % of -1.48% as of Aug. 25, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Nanjing Leads Biolabs Co and its competitors. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #480 out of 1380 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Nanjing Leads Biolabs Co's 6-1 Month Momentum % too high?
Nanjing Leads Biolabs Co's current 6-1 Month Momentum % is -1.48%. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #480 out of 1380 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's 6-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #480 out of 1380 companies for 6-1 Month Momentum %. This puts Nanjing Leads Biolabs Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current 6-1 Month Momentum % is -1.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current 6-1 Month Momentum % of -1.48%. The current 6-1 Month Momentum % is -1.48%. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current 6-1 Month Momentum % is -1.48% as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
